Intracorporeal lithotripters
This article was originally published in The Gray Sheet
Executive Summary
Preamendments Class III device (21 CFR 876.4480) is among the products proposed for Class II status as part of a mass reclassification effort by FDA, staffers say. A proposed rule listing the 38 preamendments, Class III devices to be downclassified is expected in January. A guidance document for intracorporeal lithotripters released on the FDA website Nov. 30 will serve as the special control for the device following its placement into Class II. The guidance codifies what FDA has previously required for 510(k)s for lithotripters
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.